Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW003 vs Semaglutide in Chinese Adults With Obesity
NCT07073417Phase 2Active, not recruiting
- Sponsor
- Sciwind Biosciences
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ecnoglutide in obesity (2 arms), sponsored by Sciwind Biosciences. Primary endpoint: Percentage change in body weight relative to baseline at 48 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
ecnoglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07073417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073417.